Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?

The "Magnificent Seven," a group of market-leading tech companies, is so named for several reasons. Here are three: First, they've all delivered outsized returns over the past decade or so. Second, all seven are leaders in their respective niches of the tech sector. Third, they generally boast excellent growth prospects.

Now, suppose we wanted to create a "Magnificent Seven" list in the biotech industry. Which companies would make the cut? I have no doubt that the following three drugmakers would feature prominently: Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO).